- Initiatives undertaken by corporate organizations to support photopheresis research to expand growth avenues in photopheresis products market
- High prevalence of cutaneous T-cell lymphoma, increasing number of organ transplants, and favorable reimbursement policies to translate into promising growth for photopheresis products market at 5.3% CAGR from 2019- 2027
ALBANY, N.Y., July 20, 2021 /PRNewswire/ -- Primarily, the demand for photopheresis products stems from the FDA approval of extracorporeal photopheresis (ECP) or photopheresis for the treatment of advanced cutaneous T-cell lymphoma (CTCL). For the treatment of CTCL, white blood cells are collected from the blood, mixed with photosensitizer and treated with UV light.
Besides CTCL, the leukapheresis-based therapeutic procedure has shown efficacy for other disorders, including solid organ transplant rejection, graft versus host disease, atopic dermatitis, and Crohn's disease. Extracorporeal photopheresis may also be used in the treatment of rheumatoid arthritis, nephrogenic systemic fibrosis, and psoriasis.
Taking a cue from such clinical indications, players in the photopheresis products market are engaged in regulatory approvals, launch of new products, M&As, and training and development initiatives. Such efforts are primarily aimed at overcoming the shortcomings of predecessor photopheresis products. This collectively will garner promising growth for the photopheresis products market, which in the near-term from 2019 to 2027 is projected to expand at 5.3% CAGR.
Photopheresis Products Market –Key Findings of the Report
Growing Use to Replace Steroid Therapy Creates New Opportunities
The increasing use of photopheresis for patients who do not respond to steroid therapy in situations of organ transplant rejection is spelling growth in the photopheresis products market. This is because photopheresis is safer therapy compared with steroids due to minimal side effects.
Increasing Research Initiatives to Delve into ECP Gathers Steam
Corporate organizations are increasingly supporting research to expand the use of photopheresis for other diseases. To gain the interest of research organizations, large corporations are adopting novel methods such as award contests. For example, in 2014, Freseinus Kabi conducted an award contest to gain interest of research organizations for advanced research in cell therapy and therapeutic apheresis. Furthermore, the company granted US$ 100,000 for a research initiative undertaken by a researcher at Dana Farber Cancer Institute for a work to investigate the use of photopheresis and low-dose interleulin for chronic GvHD.
This indirectly creates ample opportunities in the photopheresis products market.
Among the key therapeutic applications of the photopheresis products market, graft versus host disease is expected to garner leading share in the forthcoming years. This is mainly because of increasing prevalence of allogeneic stem transplant worldwide. In addition, increasing use of photopheresis therapy for organ transplant is boosting the photopheresis products market.
Cutaneous T-cell lymphoma, transplant rejections, and autoimmune diseases are some other key therapeutic areas of photopheresis products market.
Favorable reimbursement scenario for photopheresis therapy to treat high prevalence of T-cell lymphoma and GvHD in the region indirectly spurs growth in the photopheresis products market. In 2012, Medicare extended reimbursement coverage of extracorporeal photopheresis to treat bronchiolitis obliterans syndrome – a chronic lung allograft transplant dysfunction.
Photopheresis Products Market – Growth Drivers
Vast use of photopheresis for the treatment of cutaneous T cell lymphoma prevalent in large numbers primarily fuels photopheresis products market.
Extracorporeal photopheresis reckoned to be the first line of treatment for IV MF and IIB, and accepted to be effective for treating sezary syndrome patients, thus spurring growth in photopheresis products market.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."